other names for tirzepatide vs. Retatrutide: Key Differences Explained brand names of tirzepatide what

Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027 ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al

These products can be administered at a 0.5 or 1ml dose

In addition, researchers determined that participants taking retatrutide had not yet reached a weight loss plateau at 80 weeks, meaning continued treatment would likely produce further weight loss

Can I have other vaccines whilst on Wegovy

Semaglutide is FDA-approved for chronic weight management as Wegovy, used alongside reduced-calorie diet and increased physical activity

Interestingly, IGF-1 has been associated with BOTH a higher and lower risks of developing cancer risk, and the incidence of cancer itself may raise IGF-1 levels